BDM-2
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity[1].
Product Specifications
CAS Number
1643876-33-8
UNSPSC
12352005
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bdm-2.html
Concentration
10mM
Purity
99.09
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)(C)O[C@@H](C1=C(C2=CC=C(OCCC3)C3=C2)C(C4CC4)=CC=C1C)C(O)=O
Molecular Formula
C25H30O4
Molecular Weight
394.50
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human KCNC3 shRNA (UAS) - Lentiviral human KCNC3 shRNA (UAS, RFP) (100)
Lentiviral human MTRNR2L5 shRNA (UAS) - Lentiviral human MTRNR2L5 shRNA (UAS, RFP) (25)
Sodium hydroxide microprills pure EP, NF, E 524 (food and pharma grade)